Skip to content
Head to head

Alnylam Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ALNY · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

ALNY -68.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ALNYVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price143.82515.02
Change today-2.71%-1.08%
1-year return-67.7%+22.0%
Market cap$19.26B$130.58B
52-week range143.40 – 479.79412.27 – 568.67
Valuation
P/E (TTM)7.4833.14
P/E percentile, own 5-yr range79th99th
P/B5.356.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.3315.32
Net profit (TTM)$312.07M$3.88B
Revenue (TTM)$5.01B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+16.7%+11.8%
Gross margin77.3%85.5%
Operating margin19.5%33.1%
Net margin52.8%30.7%
Free cash flow (TTM)$806.31M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership104.2%96.8%
Insider activity (12mo)31 buy / 17 sell28 buy / 22 sell
Short interest (% of float)4.1%1.9%
Analyst consensus76% buy / 24% hold (25)95% buy / 5% hold (21)
Analyst price target$298 (+107%)$624 (+21%)
StockVane view
StockVane Quant RatingE (2)C (68)
Company
Employees2,5006,400
Founded20021989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.